Target Discovery and Validation
Source: Charles River
Charles River’s target discovery group has delivered novel, validated drug targets in a range of therapeutic areas for over 10 years.
By combining proprietary adenoviral technology with complex cellular assays, Charles River’s target discovery group has delivered novel, validated drug targets in a range of therapeutic areas for over 10 years. We examine the effects of introducing shRNAs (SilenceSelect) or full-length cDNAs (FLeXSelect) contained within our libraries of adenoviruses into human primary cells, differentiated stem cells or cell lines. siRNA and miRNA technologies are also available for gene knockdown studies.
Products/ Services
- Adenovirus Technology
- Human Primary Cellular Assays
- High- Content Platform- PhenoFocus
- High Content Platform
- Mechanism of Action
This website uses cookies to ensure you get the best experience on our website. Learn more